Treatment regimens for reducing risk of major adverse cardiovascular event
AssigneeAbcentra, LLC
InventorChristopher John FARINA
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of reducing the risk of a major adverse cardiovascular event (MACE) in a subject in a patient. The method includes administering to the patient orticumab following a phased dosing regimen, wherein the subject is administered orticumab as a loading dose followed by subsequent maintenance doses monthly, bimonthly, or weekly. The anti-oxLDL antibody may be administered to the subject alone or in combination with one or more additional therapeutic agents, such as one or more lipid lowering agents.
Claims46
A method for reducing the risk of a major adverse cardiovascular event (MACE) in a subject, the method comprising administering orticumab to the subject using a phased dosing schedule comprising:
- (i) a loading dose comprising 1245 mg of orticumab;
- and
- (ii) a maintenance dose comprising 1245 mg of orticumab, wherein the maintenance dose is administered to the subject monthly.
A method for reducing the risk of a MACE in a subject, the method comprising administering orticumab to the subject using a phased dosing schedule comprising:
- (i) a loading dose comprising 1245 mg of orticumab;
- and
- (ii) a maintenance dose comprising 1245 mg of orticumab administered to the subject weekly for a period of 3 weeks followed by monthly administration to the subject.
Dependencies are inferred from the claim text.